Qualyst, Inc. today announced that it has accomplished the closing of its Series B Preferred Stock Offering, bringing total funds raised through the Series A and Series B financing rounds to $5.5 million. Specific financial details relating to Series B were not disclosed. Burton Advisers Ltd. (of London) acted as the exclusive advisor and financial arranger for the Offering.
American Venture Magazine
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
Integra LifeSciences Recalls Drainage Devices Over Fragile Valves
The company warned that connections should be just “finger tight.”
Lilly Wins Approval for Liver Cancer Treatment
The approval comes after Lilly handed up results from a Phase 3 trial.
FDAnews Drug Daily Bulletin
QUALYST CLOSES SERIES B VENTURE CAPITAL FINANCING
May 5, 2006
